Insulin manufacturer Novo Nordisk has announced plans to increase insulin stocks in case of a ‘no deal’ Brexit scenario.
The biggest insulin supplier in the UK will now stock 16 weeks of insulin. This is to ensure insulin supplies for its type 1 diabetes patients are unaffected, whatever the outcome of the current Brexit negotiations.
This follows Sanofi’s announcement last month that they would be stockpiling 14 weeks’ supply instead of 10 weeks’ from April 2019.
All people with type 1 diabetes must take insulin every day. JDRF has written to relevant Government departments asking to be kept updated on potential issues affecting medical supplies due to Brexit.
Pinder Sahota, Corporate Vice President of Novo Nordisk UK said, “Our first commitment is to ensure that patients treated with our medicines remain unaffected in the event of a ‘no-deal’ Brexit. We are working closely with trade associations in the UK and the EU to ensure that the interests of our patients are at the forefront of negotiations.
Our decision to increase stock is in line with the technical notices and guidance published by the Government to industry. We are also working collaboratively with the Department of Health to ensure continuity of supply, irrespective of the outcome of Brexit negotiations.”